Henry Schein (HSIC) director reports bona fide 50-share stock gift
Henry Schein director Stanley M. Bergman reported a bona fide gift of 50 shares of Henry Schein common stock, without monetary consideration. Following this transaction, his direct holdings total 253,279 shares. The filing also details significant indirect holdings through his spouse and a 401(k) plan, emphasizing a non-market, personal transfer rather than a sale or purchase.
Henry Schein Names William K “Dan” Daniel as Chairman of the Board
Henry Schein has appointed William K “Dan” Daniel as the new independent chairman of its board, effective May 21, 2026. Daniel succeeds Stanley M Bergman, who is transitioning to chairman emeritus after 44 years of service. Daniel brings extensive executive leadership experience from the healthcare and industrial sectors, including his previous role at Danaher Corp where he oversaw its dental portfolio.
Henry Schein Elects William K. “Dan” Daniel as Independent Chairman of the Board, Succeeding Stan Bergman After 44 Years
Henry Schein, Inc. has announced the election of William K. “Dan” Daniel as the new Independent Chairman of the Board, effective May 21, 2026. This appointment follows the retirement of long-serving Chairman Stanley M. Bergman, who has been named Chairman Emeritus after 44 years with the company. The transition occurs as Henry Schein continues to implement its strategy to become a leading integrated solutions platform in healthcare, with Daniel bringing extensive executive experience from Danaher Corporation to his new role.
Henry Schein Names New Board Chairman
Henry Schein, Inc. has announced the election of William K. "Dan" Daniel as the new Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired after 44 years and was named Chairman Emeritus. Mr. Daniel brings extensive experience from the healthcare and industrial sectors, including a significant tenure at Danaher Corporation, and will focus on continuing the company's growth strategy.
Henry Schein announces the election of William K. "Dan" Daniel as independent chairman of the board
Henry Schein, Inc. has announced the election of William K. "Dan" Daniel as the independent chairman of its board. This news was published on May 22, 2026, at 8:56 am EDT. The company specializes in distributing healthcare products and services globally, with a significant presence in dental and medical equipment.
Henry Schein Names Dan Daniel Independent Chairman Following Stan Bergman’s Retirement
Henry Schein has appointed William K. "Dan" Daniel as its independent chairman, succeeding Stanley Bergman, who retired after 44 years. Daniel, with a background at Danaher Corporation and experience in dental operations, is expected to guide Henry Schein's continued growth in technology and practice-management services. This leadership change emphasizes operational execution and healthcare platform strategy as the company expands its role beyond traditional distribution.
Henry Schein appoints William Daniel as independent chairman
Henry Schein, Inc. has announced the election of William K. Daniel as its Independent Chairman of the Board, effective May 21, 2026. Daniel succeeds Stanley M. Bergman, who retired after 44 years and was named Chairman Emeritus. Daniel joined the board in May 2025 and previously served as Executive Vice President at Danaher Corporation, overseeing its dental portfolio.
Dan Daniel becomes Henry Schein (HSIC) independent chair as Bergman retires
Henry Schein, Inc. announced that William K. “Dan” Daniel has been elected as Independent Chairman of the Board, effective May 21, 2026. This follows the retirement of long-time director Stanley M. Bergman, who served for 44 years and has been named Chairman Emeritus. The company also reported the results of its 2026 Annual Meeting of Stockholders, including the re-election of directors, approval of executive compensation, and ratification of BDO USA, P.C. as its independent registered public accounting firm.
Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board
Henry Schein, Inc. announced the election of William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired after 44 years and was named Chairman Emeritus. Daniel brings extensive healthcare and industrial leadership experience, including 14 years at Danaher Corporation, and will build upon Bergman's legacy while supporting the company's growth strategy.
Henry Schein (HSIC) director Stanley Bergman gifts 1,040 shares
Henry Schein director Stanley M. Bergman gifted 1,040 shares of common stock on May 19, 2026, a non-market transaction without consideration. Following this gift, Bergman directly holds 253,329 shares, with additional indirect holdings through a 401(k) plan and entities related to his spouse. The transaction is categorized as a bona fide gift, with no apparent positive or negative filing impact or sentiment mentioned in the report.
Henry Schein Governance Push Meets Discounted Valuation And Mixed Share Performance
A shareholder proposal at Henry Schein (NasdaqGS:HSIC) seeks to implement a simple majority voting standard, which the board opposes. This comes as the stock trades at a significant discount to analyst targets and fair value, despite recent share price gains over the past week. The outcome of this governance push could impact future shareholder influence and engagement with the board.
Henry Schein Governance Push Meets Discounted Valuation And Mixed Share Performance
Henry Schein is facing a shareholder proposal to switch to simple majority voting, which the board opposes. This governance debate unfolds as the stock trades at a discount to analyst targets and fair value, despite mixed recent share performance. The outcome could significantly impact shareholder influence on company decisions and future engagement with the board.
Dentsply Sirona Inc stock (US24906P1093): dental specialist reacts to latest quarterly results
Dentsply Sirona Inc.'s recent Q1 2026 results show modest organic growth, driven by digital dentistry and specialty products, with adjusted EPS slightly above guidance. The company, a key player in dental technology, reaffirmed its full-year 2026 guidance and 2025 targets, indicating confidence despite macroeconomic uncertainties. The stock's muted reaction reflects investors weighing earnings upside against a cautious demand environment.
Henry Schein stock (US42548G1040): Q1 2026 results and outlook update put margins in the spotlight
Henry Schein has released its Q1 2026 financial results and updated its full-year outlook, drawing investor attention to profitability, demand trends in the dental and medical sectors, and ongoing cost pressures. The company operates as a key distributor of healthcare products and services, primarily for office-based dental and medical practitioners, and its performance is sensitive to procedure volumes and economic conditions. Analysts and investors are closely monitoring how Henry Schein navigates these factors while investing in technology and services.
Henry Schein Stock: Is Wall Street Bullish or Bearish?
Henry Schein, Inc. (HSIC) has underperformed the broader market and a healthcare ETF over the past year, despite a stock gain after stronger-than-expected Q1 results driven by increased revenue and adjusted EPS. Analysts maintain a "Moderate Buy" consensus rating for HSIC, with an average price target indicating a significant potential upside from current levels. The company's Q1 performance was boosted by dental procedure volumes and merchandise price increases, offsetting weakness in the medical segment.
Henry Schein stock (US42548G1040): Q1 results and outlook update draw investor focus
Henry Schein (HSIC) has drawn investor attention after reporting its Q1 2026 results and updating its full-year outlook. The company, a major healthcare distributor for dental, medical, and animal-health customers, faces scrutiny over margins, demand, and cost pressures despite stable top-line trends. Investors are focused on how management addresses operating discipline and cost control, especially given analyst ratings and institutional activity.
Henry Schein stock (US42548G1040): dental distributor in focus after latest earnings update
Henry Schein is gaining renewed investor attention following its latest quarterly results and updated full-year outlook. The company, a major dental and medical distributor, highlighted solid demand but also ongoing cost pressures and one-off items. Investors are focusing on margin trends, demand in its core distribution segments, and the impact of restructuring and cybersecurity costs.
Henry Schein (HSIC) Is Up 5.4% After Reaffirming 2026 Guidance And Completing Major Buyback Program
Henry Schein (HSIC) saw its stock rise 5.4% after reaffirming its 2026 earnings guidance, projecting 3% to 5% sales growth over 2025, and completing a major $3.10 billion share buyback program. The company reported modest Q1 2026 sales and flat earnings, with management emphasizing strong dental segment momentum, ongoing cost-saving, and AI initiatives, including a target of $200 million in operating improvements. Investors are looking for continued execution on these value-creation efforts and watching how dental growth offsets softer medical segments.
Henry Schein stock (US42548G1040): dental distributor in focus after latest quarterly update
Henry Schein, a major dental and medical distributor, recently released new quarterly figures and an updated outlook, drawing investor attention. The article examines the company's business model, key revenue drivers in its dental and medical segments, and the impact of factors like inflation and procedure volumes on its performance. It concludes that while Henry Schein maintains a strong position through recurring sales and technology offerings, it faces ongoing challenges from economic cycles and competitive pricing.
Henry Schein stock (US42548G1040): dental distributor focuses on margin recovery after latest earnings
Henry Schein, a major dental and medical products distributor, recently reported its quarterly results, emphasizing margin recovery and operational efficiency in its dental and medical businesses. The company's core model relies on scale, logistics, and a broad product portfolio, including consumables, equipment, and practice management solutions, with a growing focus on higher-value services and technology. For US investors, Henry Schein offers exposure to office-based healthcare, with its performance influenced by dental practice investment trends, US economic conditions, and the company's ability to execute on cost control and capital spending.
Henry Schein stock (US42548G1040): dental distributor in focus after latest earnings
Henry Schein, a major distributor of dental and medical products, recently reported its quarterly results, which highlighted stable demand in core dental supplies and continued investment in technology solutions. The company's business model combines the distribution of consumables, equipment, and pharmaceuticals with logistics and customer support services, alongside a growing technology and value-added services segment. For investors, Henry Schein offers exposure to trends in dental visits, physician office activity, and the digitalization of healthcare practices, with revenue drivers spanning recurring supplies, equipment sales, and higher-margin software subscriptions.
Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness
Henry Schein is seeing strong momentum in its dental business and is committed to achieving $125 million in net run-rate value creation benefits by year-end, despite softness in its medical segment due to a weaker respiratory illness season. CEO Fred Lowery is focusing on customer engagement, AI integration, and commercial alignment to drive future growth and enhance profitability. The company expects operational savings to build in the second half of the year, with an emphasis on gross profit optimization and strategic M&A in high-growth areas.
Lone Peak Global Investors Liquidates Entire Thermon Group Position in Q1 2026 - News and Statistics
Lone Peak Global Investors has fully divested its stake in Thermon Group in Q1 2026, selling approximately 430,230 shares valued at $20.05 million. This decision follows a 120% surge in Thermon's stock over the past year, significantly outperforming the S&P 500's 25% increase. Despite Thermon's strong financial performance and growth in AI infrastructure and industrial electrification, the fund opted to reallocate capital after substantial gains.
Lone Peak Global Investors Discloses $24M KBR Stake in SEC Filing - News and Statistics
Lone Peak Global Investors has acquired a new stake in KBR, purchasing 584,372 shares valued at approximately $24.00 million. This investment, representing 3.59% of Lone Peak's reportable assets, indicates a belief that the market undervalues KBR, especially considering its planned breakup and government-focused contracts. Despite KBR's recent stock underperformance and a Q1 revenue decline, the company maintains a strong backlog and continues to secure significant contracts in defense, AI, and energy transition, with a tax-free spin-off planned for its Mission Technology Solutions business.
What Lone Peak’s $20 Million Thermon Exit Could Signal After Record Earnings
Lone Peak Global Investors fully exited its position in Thermon Group (NYSE:THR), selling approximately 430,230 shares for an estimated $20.05 million. This divestment occurred after Thermon's stock surged 120% over the past year and the company reported record quarterly revenue and bookings, raising questions about whether investors are rotating capital despite strong underlying business momentum. Thermon specializes in industrial process heating solutions and is experiencing accelerated demand linked to data centers, electrification, LNG, and power infrastructure.
A Look At Henry Schein (HSIC) Valuation After Solid Q1 Update And Reaffirmed Guidance
Henry Schein (HSIC) is currently trading at a discount to its estimated intrinsic value and analyst targets despite solid Q1 results and reaffirmed guidance. The company's focus on high-margin businesses like Specialty Products and Technology is expected to drive earnings growth, contributing to a "fair value" narrative of $90.21 per share. However, potential risks such as competitive pricing or regulatory setbacks could challenge this optimistic outlook.
Dentsply Sirona stock (US24906P1093): dental specialist updates 2026 guidance after solid quarter
Dentsply Sirona has updated its 2026 financial targets following a strong start to the year and advancements in its efficiency program, based on its Q1 2024 results and subsequent investor communications. The company reported net sales of roughly $953 million and adjusted EPS of $0.42 for Q1 2024, maintaining its full-year 2024 guidance and linking 2026 goals to continued restructuring and investments in digital workflows. Key revenue drivers include imaging and CAD/CAM systems, consumables, implants, and clear aligners, with an emphasis on integrated solutions and disciplined capital allocation.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)
Three analysts from Bank of America Securities have provided bullish outlooks on healthcare companies Henry Schein (HSIC), Insulet (PODD), and Gilead Sciences (GILD). Henry Schein received a Moderate Buy consensus with a 25.2% upside, Insulet a Moderate Buy with a 76.2% upside, and Gilead Sciences a Strong Buy with a 19.5% upside, highlighting positive sentiment in the sector.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)
Three analysts from Bank of America Securities have issued bullish ratings on Henry Schein (HSIC), Insulet (PODD), and Gilead Sciences (GILD) within the Healthcare sector. Allen Lutz maintained a Buy rating on Henry Schein, Travis Steed maintained a Buy rating on Insulet, and Tazeen Ahmad maintained a Buy rating on Gilead Sciences, with all three stocks showing significant upside potential based on average price targets.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)
Three healthcare companies, Henry Schein (HSIC), Insulet (PODD), and Gilead Sciences (GILD), have received bullish sentiments from analysts. Bank of America Securities analysts maintained Buy ratings for all three companies, noting significant upside potential based on average price targets. Other firms like Piper Sandler and Benchmark Co. also issued Buy ratings, underscoring analyst confidence in these stocks.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD)
This article highlights bullish sentiments from financial analysts on three healthcare companies: Henry Schein (HSIC), Insulet (PODD), and Gilead Sciences (GILD). Analysts from Bank of America Securities maintained Buy ratings for all three, citing potential upsides ranging from 19.5% to 76.2% based on average price targets. The report details specific analyst ratings, price targets, and consensus recommendations for each company.
An Insider Of Henry Schein Picks Up 100% More Stock
Henry Schein insider William Daniel recently purchased US$692k worth of stock, increasing his holding by 100%. This significant buy comes despite more insider selling than buying overall at the company in the past year, though a large sale by the Chairman was at a higher price than the current stock value. Henry Schein maintains high insider ownership at 1.5%, valued at approximately US$117 million.
An Insider Of Henry Schein Picks Up 100% More Stock
Henry Schein (NASDAQ:HSIC) insider William Daniel recently doubled his holdings by purchasing US$692k worth of stock at US$69.19 per share. While this shows confidence, the company has seen more insider selling than buying over the past year, with the Chairman of the Board selling US$4.0m worth of shares at a higher price. Despite high insider ownership, the history of share sales and more recent selling activity give some pause.
An Insider Of Henry Schein Picks Up 100% More Stock
An insider at Henry Schein, William Daniel, recently purchased US$692k worth of stock, increasing his holding by 100%. This significant buy suggests strong confidence, despite a pattern of more insider selling than buying over the last year, including a US$4.0m sale by the Chairman. The article notes that while insider ownership is good at 1.5%, the overall insider transaction trend warrants caution.
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
Henry Schein One has released its 2026 Catalyst Index, an annual report indicating that clinical performance, rather than scale or efficiency, is the primary driver of growth for dental practices in a slower economy. The report highlights that top performers achieve 75% case acceptance compared to the industry average of 45%, emphasizing consistent clinical execution and patient trust. It challenges the assumption that scale alone leads to better outcomes and reveals a decline in patient retention despite improved operational metrics.
3 Reasons CZR is Risky and 1 Stock to Buy Instead
This article analyzes Caesar's Entertainment (CZR) stock, noting its recent outperformance but advising caution due to long-term revenue growth falling short of sector standards and high debt levels. Despite improved Return on Invested Capital (ROIC), the company's $24.93 billion debt and 7x net-debt-to-EBITDA ratio increase risk, leading the author to suggest it is overvalued at 141x forward P/E and recommend looking into alternative stocks.
Henry Schein Inc (HSIC) Stock Up 4.5% and Still Undervalued -- G
Henry Schein Inc (HSIC) saw its stock rise by 4.5% to $72.61, and GuruFocus assessment indicates it is still modestly undervalued with a GF Value of $82.89, representing a 12.4% margin of safety. Despite a strong GF Score of 82/100, concerns include a low predictability rating of 1 star and recent insider activity showing $8.6 million in sales versus $0.7 million in buys over the last three months. Investors are advised to consider these mixed signals along with the attractive valuation.
Henry Schein Inc. stock outperforms competitors on strong trading day
Shares of Henry Schein Inc. (HSIC) increased by 4.55% to $72.61, outperforming the S&P 500 Index and the Dow Jones Industrial Average on a positive trading day. This marks the stock's third consecutive day of gains. The article details the stock's performance relative to the broader market indices.
Henry Schein One Releases 2026 Catalyst Index
Henry Schein One has released its 2026 Catalyst Index, an annual benchmarking report for dental organizations. The report emphasizes that clinical execution, rather than scale alone, is the primary driver of growth in a slower economy, with top performers achieving significantly higher case acceptance rates. It also highlights a growing disconnect between operational efficiency gains and declining patient retention.
Sally Beauty Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance
Sally Beauty Holdings, Inc. has seen its stock valuation revised, with the current price at $14.03. The company has delivered a strong 68.02% stock return over the past year, significantly outperforming the S&P 500's 30.63%. Key financial metrics like a P/E ratio of 7 and an ROE of 22.44% indicate robust performance compared to its peers in the retail sector.
Ananym urges BWX Technologies to commercialize reactor design, says shares could double
Activist investor Ananym Capital Management believes BWX Technologies' stock could double if it commercializes its previously archived mPower nuclear reactor design. With soaring demand for clean energy, especially from data centers, Ananym argues that BWX Technologies could either be a supplier, increasing share value by 45%, or lead the market in pressurized water small modular reactors, doubling its value. The investment firm's co-founders, Alex Silver and Charlie Penner, have a history of successful activist campaigns.
[Form 4] HENRY SCHEIN INC Insider Trading Activity
This article details an insider trading activity for HENRY SCHEIN INC (HSIC) based on a Form 4 filing. Insider DANIEL WILLIAM K, a director, purchased 10,000 shares of common stock for $69.19 per share, totaling approximately $692,000. Following this transaction, Daniel William K holds 20,000 shares indirectly through a trust and 5,426 shares directly.
Henry Schein beats Q1 earnings with $1.32 EPS, 6.3% revenue growth
Henry Schein reported strong Q1 2026 results, exceeding analyst expectations with a non-GAAP EPS of $1.32 and a 6.3% rise in revenue to $3.37 billion. The growth was primarily driven by its Global Dental Distribution segment, which saw a 9% year-over-year increase. The company reaffirmed its full-year guidance, indicating confidence under its new CEO, Frederick M. Lowery.
5 Must-Read Analyst Questions From Henry Schein’s Q1 Earnings Call
Henry Schein's Q1 results surpassed analyst expectations, driven by strong performance in U.S. dental and global technology segments, despite a lighter flu season impacting the medical business. The article highlights five key analyst questions from the earnings call, focusing on topics like gross margin sustainability, specialty product growth, strategies for sustained earnings growth without restructuring, trends in dental implants, and demand for digital dental equipment. Future catalysts include AI and cloud-based dental software adoption, cost savings initiatives, and recovery in medical sales.
Henry Schein Inc. stock underperforms Monday when compared to competitors
Shares of Henry Schein Inc. (HSIC) fell by 2.58% to $68.99 on Monday, despite a positive overall trading session for the stock market, with both the S&P 500 and Dow Jones Industrial Average rising. The company's stock closed 22.73% below its 52-week high of $89.29, achieved on February 24th.
McKesson Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
McKesson Corporation announced yearly results where statutory earnings per share beat analyst expectations, despite revenue being in line with forecasts. Analysts have since updated their models, downgrading revenue estimates for 2027 but upgrading EPS forecasts, suggesting increased optimism regarding the company's earnings power. Despite these adjustments, the average price target remained unchanged, indicating no significant impact on the company's long-term valuation.
Henry Schein stock (US42548G1040): Dental and medical distributor reports Q1 results and raises outl
Henry Schein reported modest Q1 2026 revenue growth and raised its full-year outlook, driven by resilient demand in dental and medical markets. The company's adjusted diluted EPS of $1.85 surpassed estimates, leading to an increased full-year EPS guidance of $7.70-$7.90. This reflects strength in dental practice activity, steady medical supply demand, and effective integration of acquisitions.
Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next
Henry Schein, Inc. shareholders may be disappointed after a recent 5.5% stock drop despite an 8.1% EPS beat. Analysts have updated their forecasts, showing increased optimism for earnings per share in 2026, though revenue estimates remain unchanged, and the consensus price target has not shifted significantly. The company is expected to accelerate revenue growth but still lag behind the broader industry.
Henry Schein Inc stock (US8064071025): Dental and medical distributor reports Q1 results and raises outlook
Henry Schein Inc reported modest revenue growth in Q1 2026 and raised its full-year outlook, driven by steady demand for dental and medical products and disciplined cost management. The company's dental consumables and equipment segment remains its largest revenue driver, complemented by medical supplies and technology solutions. Investors can view Henry Schein as an exposure to the resilient dental and outpatient medical supply chain, though its performance is influenced by macroeconomic factors.
Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next
Henry Schein, Inc. shares fell 5.5% despite reporting an 8.1% EPS beat, with statutory profit of US$0.92 per share exceeding expectations. Analysts have updated their forecasts, maintaining revenue estimates at US$13.7b for 2026 but raising EPS expectations to US$4.20, an increase from the previous US$3.96. Despite the improved EPS outlook, the consensus price target of US$87.21 remains unchanged, and the company’s future revenue growth is projected to be slower than the broader industry.
